Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Equity (2022 - 2025)

InMed Pharmaceuticals (INM) has 4 years of Return on Equity data on record, last reported at 0.72% in Q4 2025.

  • For Q4 2025, Return on Equity rose 36.0% year-over-year to 0.72%; the TTM value through Dec 2025 reached 0.72%, up 36.0%, while the annual FY2025 figure was 0.72%, 0.0% changed from the prior year.
  • Return on Equity reached 0.72% in Q4 2025 per INM's latest filing, down from 0.66% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.51% in Q1 2024 and bottomed at 5.55% in Q3 2023.
  • Average Return on Equity over 4 years is 1.53%, with a median of 1.08% recorded in 2024.
  • Peak YoY movement for Return on Equity: crashed -364bps in 2023, then skyrocketed 477bps in 2024.
  • A 4-year view of Return on Equity shows it stood at 1.34% in 2022, then crashed by -197bps to 3.97% in 2023, then soared by 73bps to 1.08% in 2024, then skyrocketed by 33bps to 0.72% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.72% in Q4 2025, 0.66% in Q3 2025, and 0.8% in Q2 2025.